$VEEV

Veeva Systems officer proposes $1.34M share sale

Veeva Systems officer Daniel Rizzo filed a notice to sell 4,841 shares, valued at $1.34M, acquired from restricted stock vesting between 2020 and 2026. The sale is planned for October 2, 2026, with 161.9M shares outstanding.

Original reporting
Published Oct 2, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 3, 2026, 7:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$VEEV
Neutral
medium confidence
Mentioned
$VEEV
Relevance
5/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$VEEVNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly, but it adds to the flow of insider activity data.

02

Market read

A small insider sale that may cause slight short‑term pressure but is not a major catalyst.

03

What to watch

Potential tax‑planning motive or portfolio rebalancing unrelated to company fundamentals.

Relevance 5/10Novelty 5/10Timing: post‑market today

Background

Form 4 filings disclose insider transactions; traders watch for signals of confidence or distress.

Company-level read

Ticker impact

$VEEVNeutralMedium confidence
Context

Officer Daniel Rizzo filed a Form 4 to sell 4,841 shares worth $1.34 M, a new insider‑sale disclosure.

Expected impact

likely slight downward pressure as the market prices the insider sale.

Evidence & confidence

The sale size is small relative to VEEV's market cap, but insider sales can trigger short‑term sell‑offs.

Market effects

Minimal impact on the broader cloud‑software sector.

No discernible regional effect.

Limited to VEEV investors.

Counterpoint

The sale may be routine and not indicative of broader concerns.

Key entities

  • Daniel Rizzo

    Veeva Systems officer filing the sale.

Related articles

$VEEVMed

CFRA upgrades Veeva Systems (VEEV) to a Buy

CFRA upgraded Veeva Systems (VEEV) to Buy with a new price target. The consensus rating is Moderate Buy with an average target of $293.57. Veeva reported Q2 revenue of $927.96M and net profit of $273.43M, up from $789.08M and $200.31M last year. Insider sentiment is negative, with 63 insiders selling shares.

$VEEVHighAI 8/10

Michael Burry Remains Bullish on Veeva but Trimmed His Position. What This Means for VEEV Stock.

Veeva Systems reported a 37% increase in net income to $273.4M and raised fiscal 2027 revenue guidance to $3.682B-$3.687B. Michael Burry trimmed his position but remains bullish, citing the company's intrinsic value and growth potential. Analysts expect Q3 EPS of $1.68 and have raised price targets, with a consensus 'Moderate Buy' rating and $292.52 average target.

$VEEVMedAI 8/10

Veeva Rises on Sales and Margin Gains, Guidance Raise

Veeva Systems (VEEV) reported Q2 fiscal 2027 revenue of $928M, up 18% YoY, with non-GAAP operating income of $415.9M. The company raised guidance to $3.687B in revenue and $9.21 in non-GAAP EPS. VEEV shares have risen 25% YTD, supported by strong institutional demand and robust fundamentals, including 3-year sales and EPS growth rates of 14.1% and 21.6%, respectively.

$VEEVHighAI 8/10

Watch Veeva, CrowdStrike, and More

Veeva Systems (VEEV) reported Q2 non-GAAP EPS of $2.35, revenue growth of 17.6% Y/Y to $928M, and raised its Q3 revenue forecast. CrowdStrike (CRWD) posted 25.6% Y/Y revenue growth to $1.47B. Dycom Industries (DY) fell 11.6% despite 45.6% Y/Y revenue growth to $2.01B due to segment pressures and higher costs.

$VEEVHighAI 8/10

Veeva (VEEV) Q2 2027 Earnings Call Transcript

Veeva Systems (VEEV) reported Q2 2027 revenues of $928.0 million, up 18% YoY, driven by growth in commercial and R&D segments. Subscription revenues rose 16% to $766.8 million. Non-GAAP operating income was $415.9 million, with a 44.8% margin. The company raised FY 2027 revenue guidance to $3.682B-$3.687B and EPS guidance to $9.21. Management highlighted strong adoption of Vault CRM and Data Cloud solutions, with 12 top 20 biopharmas committed to Vault CRM. Risks include the launch of the new Fa